Turboclav® 250 Tablet: Each film coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 250 mg and Clavulanate Potassium USP equivalent to Clavulanic Acid 62.5 mg.
Turboclav® 500 Tablet: Each film coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 500 mg and Clavulanate Potassium USP equivalent to Clavulanic Acid 125 mg.
Turboclav® (Cefuroxime and Clavulanic Acid) is a well-characterized and effective antibacterial agent, which has broad-spectrum bactericidal activity against a wide range of common pathogens, including β-lactamase producing strains. Cefuroxime has good stability to bacterial β-lactamase and consequently is active against many ampicillin-resistant and amoxicillin-resistant strains.
Turboclav® (Cefuroxime and Clavulanic Acid) is indicated in the treatment of.:
Adolescents & Adults
Community acquired pneumonia
Uncomplicated skin & skin-structure infections
MDR Typhoid fever
Uncomplicated urinary tract infection
Uncomplicated gonorrhea
Lyme disease
Pediatric patients (3 months to 12 years)
Turboclav® may be administered without regard to meals.
Probenecid: Concomitant administration of probenecid with cefuroxime increases the area under the serum concentration versus time curve by 50%.
Antacids: Drugs that reduce gastric acidity may result in a lower bioavailability of Turboclav® compared with that of fasting state and tend to cancel the effect of postprandial absorption.
Oral contraceptives: In common with other antibiotics, cefuroxime may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone.
Generally Cefuroxime and Clavulanic acid are well tolerated. However, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur.
Excessively large doses of all Cephalosporins can cause cerebral irritation and may cause convulsions. This complication is unlikely to occur in routine practice unless the patient is in renal failure. Hemodialysis or peritoneal dialysis can remove Turboclav®.
While all antibiotics should be avoided in the first trimester if possible, Turboclav® has been safely used in later pregnancy to treat urinary and other infections. Turboclav® is excreted in human milk, and consequently caution should be exercised when Turboclav® is administered to a nursing mother.
As with other antibiotics, prolonged use of Turboclav® may result in the over growth of nonsusceptible organisms (e.g. *Candida*, *Enterococci*, *Clostridium difficile*) which may require interruption of treatment.
Keep out of the reach of children. Keep in a cool and dry place. Protect from light.